While no guidelines exist on the management of co-occurring CKD and stroke, current practice recommendations include aggressive blood pressure management with a goal <120/80, aggressive lipid management in non-dialysis-dependent patients, treatment with an SGLT-2 inhibitor in patients with diabetic CKD and an estimated glomerular filtration rate >30, and a low threshold for screening for Afib [97]. This evidence concerns the gene SLC5A2 and chronic kidney disease.